Welcome to our dedicated page for Maze Therapeutics news (Ticker: MAZE), a resource for investors and traders seeking the latest updates and insights on Maze Therapeutics stock.
Maze Therapeutics (MAZE) is a clinical-stage biopharmaceutical company pioneering precision medicines through human genetics research, focusing on renal, cardiovascular, and metabolic diseases. This page serves as the definitive source for verified corporate announcements, clinical trial developments, and strategic updates.
Investors and researchers gain streamlined access to essential information about MAZE's innovative pipeline, including MZE829 and MZE782 programs targeting chronic kidney disease. The curated news collection provides insights into clinical milestones, regulatory progress, and partnership announcements while maintaining compliance with financial disclosure standards.
Key updates include earnings reports, research breakthroughs from the proprietary Compass platform, and biomarker-driven trial results. All content undergoes rigorous verification to ensure accuracy and relevance for stakeholders monitoring genetic medicine advancements.
Bookmark this page for real-time updates on MAZE's progress in developing small molecule therapies that address high-risk genetic variants. Visit regularly to stay informed about this clinical-stage innovator's contributions to precision medicine.
Maze Therapeutics (MAZE) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical programs. The company successfully completed an upsized IPO in February 2025, raising $140 million in gross proceeds at $16.00 per share, following a $115 million Series D financing in November 2024.
Key pipeline developments include the Phase 2 HORIZON trial of MZE829 for APOL1 Kidney Disease (AKD), with initial data expected in Q1 2026, and ongoing Phase 1 trials of MZE782 for chronic kidney disease (CKD) and phenylketonuria (PKU), with data expected in H2 2025.
Financial highlights for 2024 include license revenue of $167.5 million, primarily from a Shionogi agreement, and a net income of $52.2 million. Cash position stood at $196.8 million as of December 31, 2024, with runway expected into H2 2027.
Maze Therapeutics (NASDAQ: MAZE) has initiated patient dosing in its Phase 2 HORIZON clinical trial, evaluating MZE829, an oral APOL1 inhibitor for APOL1 kidney disease (AKD). The trial targets a condition affecting over one million patients in the United States.
The HORIZON Study employs an open-label basket design, enrolling AKD patients with two high-risk APOL1 alleles (G1, G2), stratified by clinical phenotype and proteinuria levels. The study includes patients with severe disease, nephrotic range proteinuria, FSGS, hypertensive nephropathy, and diabetic kidney disease, marking the first trial of a small molecule APOL1 inhibitor in diabetic AKD patients.
The primary endpoint focuses on reducing proteinuria, measured by a 30% or greater reduction in urinary albumin-to-creatinine ratio (uACR) at week 12. Maze anticipates an interim data readout in Q1 2026.
Maze Therapeutics (Nasdaq: MAZE), a clinical-stage biopharmaceutical company focused on developing precision medicines for renal, cardiovascular and metabolic diseases, has announced the pricing of its upsized initial public offering. The company is offering 8,750,000 shares of common stock at $16.00 per share, expecting to raise gross proceeds of $140.0 million.
The shares will begin trading on the Nasdaq Global Market on January 31, 2025, under the symbol 'MAZE'. The company has granted underwriters a 30-day option to purchase up to an additional 1,312,500 shares. The offering is expected to close on February 3, 2025. J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities are serving as joint bookrunning managers for the IPO.
FAQ
What is the current stock price of Maze Therapeutics (MAZE)?
What is the market cap of Maze Therapeutics (MAZE)?
